StemCells Inc Profile

0.02  5.12%
10 Days Price Trend
May 4, 2016

StemCells Market Sensitivity

As market goes up, the company is expected to significantly outperform it. However, if the market returns are negative, StemCells will likely underperform.
One Month Beta |Analyze StemCells Inc Demand Trend
Check current 30 days StemCells correlation with market (NYSE)
β = 1.2112
StemCells Large BetaStemCells Inc Beta Legend

Selected StemCells Inc Income Statement Over Time

Key Fundamentals

StemCells Against Markets

StemCells Leadership

Martin McGlynn CEO, Director, Member of Strategic Transactions Committee, CEO of Stemcells California Inc and President of Stemcells California Inc
John Schwartz Independent Chairman of the Board, Ph.D
More Executives

StemCells Diversification Suggestion

Use StemCells to protect against small markets fluctuations. The stock experiences very speculative upward sentiment.. Check odds of StemCells to be traded at $0.266 in 30 days

StemCells Daily Price Distribution

The median price of StemCells for the period between Mon, Apr 4, 2016 and Wed, May 4, 2016 is 0.263 with a coefficient of variation of 12.11. The daily time series for the period is distributed with a sample standard deviation of 0.03, arithmetic mean of 0.27, and mean deviation of 0.02. The Stock received some media coverage during the period.

StemCells Summary

StemCells Inc [STEM] is traded on Nasdaq Capital Markets in USA. It is located in Newark, CA and employs 69 people. The company currently falls under 'Micro-Cap' category with current market capitalization of 36.69 M. StemCells Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 139.22 M outstanding shares of which 4.8 M shares are at this time shorted by private and institutional investors with about 0.93 trading days to cover.

StemCells Inc Accumulated Other Comprehensive Income Over Time

StemCells Inc. a biopharmaceutical company engages in the research development and commercialization of cellbased therapeutics and related technologies. more
NameStemCells Inc
InstrumentUSA Stock
ExchangeNasdaq Capital Markets
Contact Number510 456 4000
Analyst ConsensusStrong Buy 4 Opinions
Macroaxis AdviceStrong Hold  Under Valued
CurrencyUSD - US Dollar
Did you try this?
Run Idea Analyzer Now

Idea Analyzer

Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Hide   View All   NextLaunch Idea Analyzer
StemCells Analyst Recommendations
Target PriceAdvice# of Analysts
1.75Strong Buy4
StemCells Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
StemCells Analyst Advice  
StemCells Alerts
Equity Alerts and Improvement Suggestions
StemCells Inc appears to be very risky and stock price may revert if volatility continues
StemCells Inc has some characteristics of a very speculative penny stock
StemCells Inc has high likelihood to experience some financial distress in the next 2 years
The company reported previous year revenue of 971.08 K. Net Loss for the year was (37.56 M) with profit before overhead, payroll, taxes, and interest of 116.89 K.
STEMCELLS INC currently holds about 21.19 M in cash with (30.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.2.
Latest headline from Notable Analyst Ranking Preview Pfizer Inc. StemCells Inc ...
Upcoming Events
StemCells Upcoming Company Events
Upcoming Quarterly ReportMay 3, 2016
Next Earnings ReportAugust 4, 2016
Corporate Filings
StemCells Corporate Filings
Financial Statements and Exhibits. Results of Operations and Financial Condition
Other Events. Departure of Directors or Certain Offices; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year
Company Reports
StemCells Corporate Reports
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
StemCells Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.06May 3, 2016
StemCells Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
StemCells Earnings Estimate  
Research Report
Get StemCells research report
Get StemCells research report. Reports are available in pdf format and contain fundamental information about the equity. Click Research Report to view
Pair Trading
StemCells Pair Trading Analysis
Correlation analysis and pair trading evaluation for StemCells and Gilead Sciences. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Macroaxis investing idea could easily outperform a given market if properly optimized
Explore Investing Ideas  
StemCells Corporate Directors
Irving Weissman Director
Eric Bjerkholt Independent Director
R Greer Independent Director